Horizon Heralds Stellar Launch Of TED Drug Tepezza
One Of The Best New Product Launches In Years
Executive Summary
Despite COVID-19, Horizon Therapeutics has pulled off a spectacularly successful launch of its thyroid eye disease therapy, Tepezza, thanks to pre-commercial activities that led to a high level of initial patient and prescriber awareness, and market access teams securing a decent reimbursement rate.
You may also be interested in...
Pandemic Perspectives: COVID-19 Upended Drug Launches In Ways That Will Stick
Preliminary data from IQVIA suggest 2020 was one of the weakest in recent years for new launch trajectories although drug companies tell Scrip there are some lessons learned from promoting during the pandemic.
J.P. Morgan Extras: Pandemic Impact on Launch, Production, Development And More
Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.
2020 Drug Launches, Like Everything, Will Be Remembered For COVID-19
Gilead's Veklury for the treatment of COVID-19 was a clear commercial standout among new drugs in 2020, but cancer drugs like Seagen's Padcev and Tukysa are poised for long-term potential.